Genome Explorations, A Tesis Biosciences Company, is an industry leader in providing a complete range of Molecular Diagnostics (MDx) Services to clinical institutes worldwide.
Our state of the art CLIA-certified, GLP-compliant laboratories utilize the latest Next-Generation Sequencing Platforms from Illumina and ThermoFisher. In addition our Affymetrix Microarray Platforms provide unsurpassed Digital Karyotyping and Pharmacogenomics diagnostic capabilities. Over the past 21 years Genome Explorations research Laboratories have helped develop the latest generation of cancer MDx panels enabling physicians to treat their patients with the utmost confidence.
In addition to cancer diagnostics, our scientists are working with researchers worldwide to develop NextGen sequencing panels for Prenatal Screening, Pharmacogenomics, and a variety of Cardiovascular and Hereditary disorders.
Our experienced scientists work one-on-one with scientists, researchers and clinicians to provide a ‘Complete Solution’ for Genotyping, Gene Expression and miRNA Profiling Services, from experimental design to in-depth data analysis and advanced bioinformatics.
With over 50 years of combined experience, our scientists at Genome Explorations have developed detailed standard operating procedures (SOPs) that allow us to consistently generate the highest quality, most reproducible data sets in the industry. Genome Explorations has received global acknowledgements for their achievements, and has been the industry leader in providing complete Genomics Solutions since 2001.
Genome Explorations provides both high-throughput service and comprehensive research project execution. Genome Explorations scientists and affiliates represent some of the most skilled clinical, molecular and bioinformatics researchers in the USA. Our Scientists have conducted a variety of clinical projects aimed at finding expression signatures, drug targets or underlying genotypes for Pharma/Biotech customers. Genome Explorations is a market leader in Biomarker Discovery, Companion Diagnostics Development, Novel Drug Screening and Clinical Validation programs.